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Background: Synthetic contiguous overlapping peptides (COPs) may represent an alternative to allergen extracts or
recombinant allergens for allergen specific immunotherapy. In combination, COPs encompass the entire allergen
sequence, providing all potential T cell epitopes, while preventing IgE conformational epitopes of the native allergen.
Methods: Individual COPs were derived from the sequence of Bet v 1, the major allergen of birch pollen, and its
known crystal structure, and designed to avoid IgE binding. Three sets of COPs were tested in vitro in competition
ELISA and basophil degranulation assays. Their in vivo reactivity was determined by intraperitoneal challenge in rBet v 1
sensitized mice as well as by skin prick tests in volunteers with allergic rhinoconjunctivitis to birch pollen.
Results: The combination, named AllerT, of three COPs selected for undetectable IgE binding in competition assays
and for the absence of basophil activation in vitro was unable to induce anaphylaxis in sensitized mice in contrast to
rBet v 1. In addition no positive reactivity to AllerT was observed in skin prick tests in human volunteers allergic to birch
pollen. In contrast, a second set of COPs, AllerT4-T5 displayed some residual IgE binding in competition ELISA and a
weak subliminal reactivity to skin prick testing.
Conclusions: The hypoallergenicity of contiguous overlapping peptides was confirmed by low, if any, IgE binding
activity in vitro, by the absence of basophil activation and the absence of in vivo induction of allergic reactions in
mouse and human.
Trials registration: ClinicalTrials.gov NCT01719133
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Allergen specific immunotherapy (SIT) is the only etio-
logic treatment available for IgE-mediated allergy [1].
SIT consists in the administration of incremental doses
of allergen extracts progressively leading to immune and
clinical tolerance to the allergen. The efficacy of SIT has
been largely demonstrated [2-4]. However, a number of
side effects are observed during conventional SIT [5] as
well as during ultrarush immunotherapy, where up to
30% of patients develop anaphylactic reactions, some-
times severe or even fatal [6]. While the duration of* Correspondence: francois.spertini@chuv.ch
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reproduction in any medium, provided the ortreatment may potentially be largely shortened, the
current duration lasting three to five years of monthly
injections depending on the allergen sensitivities. Differ-
ent innovative strategies recently aimed to improve both
efficacy and safety of SIT. A first approach consisted in
improving existing formulations by using, as adjuvants,
TLR agonists including monophosphoryl lipid A (MPL)
[7-9], DNA immunostimulatory sequences (CpG) [10] or
viral particles combined to CpG [11] in order to mainly
stimulate a TH1 response to a limited amount of whole
allergen extracts. In another strategy targeting specific-
ally the allergen formulation, a combination of recom-
binant major allergens appeared to improve rhinitis
combined score in patients allergic to grass pollen [12].
Interestingly immunotherapy with the recombinant majorl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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native Bet v 1 or birch pollen extract [12,13], showing that
a single allergen may potentially substitute for the whole
extract. A third line of development explored the use of
products with hypoallergenic potential as demonstrated
by reduced IgE binding capacity but conserved T cell rec-
ognition, and involved mainly T cell epitope peptides and
allergen fragments of various lengths [14-18] or point mu-
tations on IgE epitopes [19].
We previously performed a phase I trial based on the
subcutaneous injection of synthetic contiguous overlap-
ping peptides (COPs) from the major bee venom aller-
gen phospholipase A2 (PLA2) [20]. Clinical tolerance
was excellent. Immunogenicity was marked by enhance-
ment of PLA2 specific IgG4 levels, T cell hyporespon-
siveness, TH1 cytokine deviation and PLA2 peptide
specific IL-10 production. Based on this approach, we
describe in this paper the design and first clinical appli-
cation of novel sets of COPs derived from the birch
major allergen Bet v 1. Among allergic patients hyper-
sensitive to tree pollens, skin prick tests to birch pollen
extract are positive in a large majority of patients and
most of them have developed specific IgE to Bet v 1, a
member of the PRP-10 family of plant defense proteins.
In addition, hypersensitivity to birch pollen is very often
linked to allergies to other trees of the Fagales order
and at the origin of crossreactive hypersensitivities to a
large array of food allergens belonging to Rosaceae,
Juglandaceae, Corylaceae, Apiaceae or Solanaceae fam-
ilies [21-24].
Our aim in this study was to evaluate COPs hypo-
allergenicity in vitro (based on their IgE binding capacity)
and in vivo (based on their capacity to induce an allergic
reaction in animals or a positive skin test in Bet v 1 allergic
volunteers) as a preliminary study to a therapeutic phase I
clinical trial in patients with allergic rhinitis to birch
pollen.Table 1 Sequences and physico-chemical characteristics of Be
(aa sequence refers to Bet v 1.01-A, SwissProt P15494.2)
COP name Sequence
T1: aa 2-50 GVFNYETETTSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEG
T2: aa 48-118 NGGPGTIKKISFPEGFPFKYVKDRVDEVDHTNFKYNYSVIEGGP
T3: aa 106-160 VATPDGGSILKISNKYHTKGDHEVKAEQVKASKEMGETLLRAVE
T4: aa 2-85 GVFNYETETTSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEG
T5: aa 65-160 FKYVKDRVDEVDHTNFKYNYSVIEGGPIGDTLEKISNEIKIVATPD
KISNKYHTKGDHEVKAEQVKASKEMGETLLRAVESYLLAHSDA
T6: aa 2-49 GVFNYETETTSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEG
T7: aa 44-118 NIEGNGGPGTIKKISFPEGFPFKYVKDRVDEVDHTNFKYNYSVIE
T8: aa 103-160 IKIVATPDGGSILKISNKYHTKGDHEVKAEQVKASKEMGETLLRA
aa : amino acids.Material and methods
Peptides synthesis and purification
Three sets of COPs composed of peptides T1-T2-T3, T4-
T5 and T6-T7-T8 respectively (Table 1), all mapping the
whole sequence of Bet v 1 were synthesized according to
GLP recommendations by solid phase fmoc chemistry on
an Applied Biosystems 431A Peptide Synthesizer (Perkin
Elmer, Foster City, Calif) and purified as described [25].
Analytic HPLC and mass spectrometry were used to assess
the purity of each peptide (>90%). Peptides were resus-
pended in water (2 mg/ml) and frozen at −20°C in aliquots.
The equimolar combination of T1, T2 and T3, composing
the finally selected product, was named AllerT.
Animals
Four weeks-old female BALB/c mice (H-2d) were obtained
from Harlan (AD Horst, The Netherlands) and used at the
age of 6–8 weeks.
Sensitization of mice and challenge
Mice were sensitized with subcutaneous injections of
0.1 μg rBet v 1 adsorbed on 1 mg Aluminum Hydroxide
(Sigma Chemicals, St-Louis, MO, USA) up to six times
at 2 weeks intervals as previously described [26]. Two
weeks later (D84), mice were challenged i.p. either with
30 μg rBet v 1 (BIOMAY, Vienna, Austria) or 190 μg
AllerT. Rectal temperature was recorded before, 15, 30,
45 and 60 min after challenge with a digital thermom-
eter (Terumo, Tokyo, Japan). Sera were collected the
day before each treatment.
Mouse isotypic anti-rBet v 1 IgE and IgG response
Mouse serum IgE, IgG1 and IgG2a antibody responses
were determined by ELISA as previously described
[26,27]. Briefly, 96-well Nunc Maxisorp® immunoplates
(Life Technologies, Basel, Switzerland) were coated with
5 μg/ml rBet v 1. After blocking with 1% BSA, platest v 1-derived synthetic contiguous overlapping peptides
pI Mw
NGG 4.36 5295.93
IGDTLEKISNEIKIVATPDGGSILKIS 5.72 7742.76
SYLLAHSDAYN 6.29 6001.72
NGGPGTIKKISFPEGFPFKYVKDRVDEVDHTNFKYNYS 5.24 9348.49
GGSIL 5.77 6001.72
YN
NG 4.36 5141.77
GGPIGDTLEKISNEIKIVATPDGGSILKIS 5.24 8156.19
VESYLLAHSDAYN 7.03 6356.22
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namely 1:5 for IgE, 1:200 for IgG1, 1:50 for IgG2a.
Biotinylated rat anti-mouse IgE (2 μg/ml), IgG1 or
IgG2a (167 ng/ml) (PharMingen, BD-Biosciences, San
Diego, CA) were used as secondary antibodies, revealed
with extravidin alkaline phosphatase and 4-NPP sub-
strate (Sigma Diagnostic Inc., St-Louis, MO, USA) and
OD read at 405 nm using a microplate reader (Dynatech
laboratories, Chantilly, VA, USA). A titration of purified
mouse IgE (27–74, PharMingen) on microwells coated
with 2 μg/ml rat anti-mouse IgE (R35-72, PharMingen)
was used to convert OD in IgE concentration.Degranulation assays on rat basophil lines
Degranulation assay was performed as previously de-
scribed [28]. RBL-2H3 cells were plated in 96-well tissue
culture plates (4×104 cells/well) overnight. Passive sen-
sitization of RBL-2H3 cells was carried out with sera
from rBet v 1-sensitized mice at a final dilution of 1:30
for 2 h. Unbound antibodies were removed by washing
the cell layer twice in Hanks’ balanced salt solution
(Sigma-Aldrich, St-Louis, MO, USA). Degranulation of
RBL cells was induced by adding rBet v 1, individual
COP T1, T2, T3 or AllerT diluted in HBH buffer (HBSS
with 1% BSA and 10 mM HEPES) for 1h at 37°C at indi-
cated concentrations. β-hexosaminidase activity was ana-
lyzed by incubating 50 μl of cell supernatant with 50 μl
of 1.3 mg/ml 4-Nitrophenyl N-acetyl-β-D-glucosaminide
(Sigma) in citrate buffer (0.1M, pH 4.5) for 1 h at 37°C.
The reaction was stopped by addition of 100 μl glycine
buffer (0.2M glycine, 0.2M NaCl, pH 10.7) and optical
densities (OD) measured at 405 nm.Competition ELISA for rBet v1 specific hu IgE
Dilutions (1:5 to 1:10) of sera from 6 birch pollen aller-
gic patients (specific Bet v 1 IgE >15.9 kU/L, Phadia,
Uppsala, Sweden) were incubated 1h with tenfold serial
dilutions of either individual COPs (T1, T2, T3; T4, T5),
COPs combinations AllerT, T4-T5, T6-T7-T8 or rBet v 1,
starting at 10-5 M, then distributed to rBet v 1 coated
and BSA 1%-blocked 96-well immunoplates (Nunc
Maxisorp®Life Technologies, Basel, Switzerland) for 2 h
RT or overnight at 4°C. Successively and with washings
between steps, plates were incubated 1 h at RT with
biotinylated mouse anti-huIgE (Pharmingen, 5 μg/ml,
1 h at RT), Streptavidin-HRP or -alkaline phosphatase
(BD, 1:1000 or 1:8000, respectively, 30 min at RT)
and TMB (BD OptEIA, ) or 4-NPP. OD were read at
450 nm, 630 nm and 405 nm, respectively. Inhibition
of IgE binding to Betv 1 was calculated as: (OD with
competitor minus ODmin)/(OD without competitor
minus ODmin) × 100, where ODmin was determined
in wells without serum.Human basophil activation assay
The direct assay was performed using the Basotest™ assay
according to manufacturer’s instructions (Orpegen Pharma,
Heidelberg, Germany). Heparinized blood (100 μl) was first
incubated with stimulation buffer for 10 min at 37°C, and
then with 100 μl allergen solution diluted in a saline
solution for 20 min at 37°C. A dose–response curve was
performed with ten-fold dilutions of rBet v 1 or AllerT.
Formyl methionyl leucyl phenylalanine was used as a
positive control and PBS as a negative control. The acti-
vation process was stopped by incubating blood samples
at 4°C for 10 min. Samples were stained for 20 min at
4°C with 20 μl anti-IgE-PE mAb and anti-CD63-FITC.
Erythrocytes were subsequently removed by adding
2 ml lysis solution (Becton-Dickinson) and two washes
with PBS. Cells were resuspended in 200 μl PBS and at
least 103 basophils for each sample were acquired within
1 h on a FASCalibur, Becton-Dickinson. Results were
expressed as the percentage of basophils (IgE+ cells) ex-
pressing CD63. A cut-off ≥15% CD63+ IgE+ basophils
was chosen as the lower limit of positivity according to
the manufacturer. In indirect assay, 100 μl of heparin-
ized blood from a non-allergic subject was pre- incu-
bated 2 h at 37°C with 25 μl of plasma or sera from
allergic subjects before performing the Basotest™ assay
as described above.
Degranulation assays on humanised basophil cell line
RBL703/21
The assay was adapted from Ladics et al. [29] and Blanc
et al. [30]. RBL cells transfected with human FcεRI
(RBL703/21, kind gift of Dr L. Vogel, Paul-Ehrlich Insti-
tute, Germany) were plated at 105 cells/well in medium
(MEM containing glutamine and penicillin/strepto-
mycin) and incubated overnight with sera from subjects
with class 4, 5 and 6 IgE levels to birch pollen extract as
determined by ImmunoCAP (Phadia, Uppsala, Sweden).
Human serum was diluted 1/2 with 4M glucose and in-
cubated for 45 min at 56°C, centrifuged and diluted 1/5
with MEM medium before addition to RBL703/21 cells.
After washing with Tyrode’s buffer (137 mM NaCl, 2.7
mM KCl, 0.4 mM Na phosphate, 0.5 mM MgCl2, 1.4
mM CaCl2, 10 mM Hepes, 5.6 mM glucose, 0.1% BSA),
cells were incubated for one hour at 37°C with various
concentrations of rBet v 1, COPs or 0.5 μg/ml goat anti-
human IgE heavy chain antiserum (Nordic Immunology
Laboratories, Eidhoven, NL) in Tyrode’s buffer containing
50% deuterium oxide or Tyrode’s buffer alone as
control. Supernatants (30 μl) were incubated in dupli-
cates with 50 μl of substrate solution (1.3 mg/ml p-
nitrophenyl-b-D-2-acetamido-2-deoxyglucopyranozide
from Sigma in 0.1 M citrate pH 4.5) for 1 hour at 37°C.
Reaction was stopped by the addition of 100 μl of 0.2
M glycin (pH 10.7). OD was measured at 405 nm
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was calculated using the following formula: (OD sample-
ODbuffer) / (ODanti-IgE-ODbuffer) × 100.AN002 phase I clinical trial: study population
The AN002 phase I clinical trial was a single center,
open and controlled study conducted at the Centre
Hospitalier Universitaire Vaudois (CHUV) in Lau-
sanne. Volunteers (18–45 years) with at least one sea-
son history of birch pollen rhinoconjunctivitis or
asthma were recruited outside of the birch pollen sea-
son. Volunteers treated with antihistamines or medica-
tion with antihistamine activity less than 15 days prior
to skin prick testing were excluded as well as volun-
teers with peak expiratory flow (PEF) <20% of volun-
teer’s best PEF value. Birch pollen sensitization was
documented 1) by positive skin prick test to birch
pollen extract (Aquagen SQ, ALK Abello) and to rBet
v 1 (BIOMAY, Vienna, Austria), and 2) positive birch
pollen and rBet v 1-specific serum IgE (>0.35 kU/L by
ImmunoCAP assay). Inferior limits of specific IgE to
determine allergy classes 1 to 6 are 0.35, 0.7, 3.5, 17.5,
50 and 100 kU/L respectively. The clinical research
protocol was approved by the Ethical Review Board of
the Faculty of Biology and Medicine, Lausanne, and by
the Swiss National Regulatory Authority (Swissmedic)
and posted on the ClinicalTrials.gov site under the
study number NCT01719133. The primary objective of
the study was to determine the reactogenicity of se-
lected COPs by skin prick tests.Skin prick testing
Individual T1 to T5 COPs, AllerT and T4-T5 mix were
evaluated in vivo by skin prick tests following EAACI
guidelines [31]. For individual COP or mixes, a 20 μl
drop was applied onto the forearm of volunteers at 3
different dilutions in sterile PBS (10 μM, 1 μM, 0.1 μM)
and compared to skin prick tests with serial ten-folds di-
lutions (in NaCl 0.9%) of birch pollen extract (Aquagen
SQ, ALK-Abello, Horsholm, Denmark, 100’000 SQ,
10’000 SQ and 1000 SQ) and rBet v 1 (1 μM, 0.1 μM,
and 0.01 μM).Statistical analysis
In animal studies, results are expressed as mean ± SD of
6–10 mice/group. Each experiment was done at least
three times. Significance of differences between means
was determined using Student’s or non-parametric t test.
* = p<0.05; **= p<0.01; *** = p<0.001. Analysis was done
using the Prism 4.00 software for Windows (GraphPad
Software Inc., San Diego, CA, USA). Data analysis of
clinical trial AN002 was descriptive.Results
Design of the Contiguous Overlapping Peptides (COPs)
Bet v 1 is a 159 amino acid (aa) long protein present as
a mix of isoforms in pollen extracts and differing by a
few amino acids [32]. Based on the sequence X15877 of
rBet v 1.01A, the most represented Bet v 1 isoform [15],
we devised three sets of COPs with potentially disrupted
IgE conformational epitopes. We based our strategy on
Bet v 1 sequence comparison between Fagales species
showing regions of particularly high sequence conserva-
tion that may possibly contain IgE epitopes as proposed
by Spangfort et al. [33]. Three conformational regions
are at high risk of binding IgE. A first region includes aa
97–121 combined to aa 131–141; a second region en-
compasses aa 15–31 and a third region involves a loop
located at aa 41–52 homologous to the GTP-binding se-
quence GXGXXG [34]. On the other hand, T cell epi-
topes are scattered throughout the Bet v 1 sequence
except for amino acids 48–59, containing the potential
GTP binding site GXGXXG [35]. The sets of COPs T1-
T2-T3 and T4-T5 encompass the complete Bet v 1 se-
quence (Table 1). In order to conserve all potential T
cell epitopes, COPs were overlapped at their extremities
by 3, 13 and 21 aa for T1/T2, T2/T3 and T4/T5 respect-
ively. A third set of COPs, namely T6-T7-T8 was de-
rived from T1, T2 and T3 with modified extremities
(Table 1). In particular, the C-terminus of T6 was one
amino acid shorter than T1. T7 has four amino acids
added at the N-terminus compared to T2, and T8 has
three amino acids added also at the C-terminus. COPs
were either used separately or mixed in equimolar
amounts in further experiments.
Analysis of human Bet v 1 specific IgE binding to COPs by
competition assay
COPs were first tested in vitro for birch specific IgE bind-
ing by competition ELISA. Soluble rBet v 1 inhibited serum
IgE binding with EC50 ranging from 10
-14 to 10-10 M,
(Figure 1A). COPs T1, T2 and T3 either in equimo-
lar combination (AllerT) (Figure 1A) or individually
(Figure 1B) showed no competitive activity up to 10-
5 M. The same result was obtained using COPs T6,
T7 and T8 in combination (Figure 1A), indicating
that the precise ending of the COPs was not essen-
tial for reducing IgE binding. Results were compar-
able with T4 and T5 individually as competitors
(Figure 1C). Surprisingly, the combination of T4-T5
as an equimolar mix did inhibit IgE binding with
EC50 in the range of 10
-7-10-8 M, i.e. at least at con-
centration 104-fold higher than rBet v 1 (Figure 1A).
The fact that competition reaches completion sug-
gests partial refolding due to interaction of T4 and
T5 in solution, thus re-creating the original IgE epi-
tope(s).
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Figure 1 Human IgE competition assays. rBet v 1-specific IgE were measured by ELISA in sera from individual birch pollen allergic patients pre-
incubated with increasing concentrations of either rBet v 1 or COPs as indicated on the X axis. Panel A: Sera from six allergic patients (indicated
by various symbol shapes) were pre-incubated with either rBet v 1 (black symbols), AllerT (grey symbols), T4-T5 (open symbols) and T6-T8
(crossed circles). Panel B: Individual COPs T1, T2 and T3 were tested separately with serum from a representative patient as indicated in the
Figure (control rBet v 1, black circles). Panel C: Sera from three allergic individuals was reacted with either T4 or T5 (black & white symbols) alone
or control rBet v 1 (black symbols). Inhibition of binding is expressed as the inverse of the percentage of residual IgE binding to Bet v 1.
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degranulation
The capacity of COPs to induce basophil degranulation
was characterized using rat basophil leukemia cells
(RBL) [28]. Upon stimulation with rBet v 1, hexosamini-
dase accumulated significantly in the supernatant fromRBL cells primed with sera from Bet v 1-sensitized mice
(see below). On the contrary, AllerT as well as individual
COPs were unable to induce hexosaminidase release
even at ten-fold (5.7 nM, panel A) and hundred-fold
(57 nM, panel B) higher concentrations than optimal
rBet v 1 (0.57 nM, panel C) (Figure 2).
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Figure 2 Degranulation of rat basophil lines induced by AllerT and its respective individual COPs T1, T2 and T3. Beta-hexosaminidase
release was measured from RBL-2H3 cells loaded with sera obtained from r Bet v 1-sensitized mice and stimulated in panel A. with 5.7 nM rBet v 1,
T1, T2, T3, AllerT or left unstimulated, n=10; in panel B: with 57 nM rBet v 1, T1, T2, T3, AllerT or left unstimulated, n=3; panel C: Beta-hexosaminidase
release from RBL-2H3 cells loaded with 2 sera (dilutions 1:10, 1:50 and 1:100) obtained from r Bet v 1-sensitized mice and stimulated with serial
concentrations of Bet v 1. Degranulation was measured using a colorimetric assay and is expressed in OD. Median and quartiles are indicated as
horizontal bars. Data were analyzed by a non-parametric paired t test and compared to rBetv1. **p <0.01.
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Mice were sensitized by repeated injections of rBet v 1
(0.1 μg in Aluminum Hydroxide) as described previously
[28]. Bet v 1 specific IgE increased markedly after the
fourth injection to level thereafter (Figure 3A). IgG1 and
IgG2a levels started to increase after the fourth injectionA
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and C). Clinical hypersensitivity of mice was tested by
injecting i.p. 30 μg rBet v 1, using rectal temperature as a
surrogate marker of anaphylaxis [26]. As seen in Figure 3D,
a marked temperature drop was observed within 30 mi-
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Figure 4 Human basophil degranulation assay. Panel A:
Basophils from two subjects allergic to birch (circle and square
symbols) were activated by rBet v 1, AllerT, T4-T5 or T6-T7-T8 mixes
at indicated concentrations. Panel B: Basophils from a non-allergic
donor were pre-incubated with sera from 3 subjects allergic to birch
(circles, squares and triangles) and incubated with the indicated
concentrations of rBet v 1 and AllerT. Degranulation is expressed as
the percentage of CD63 positive basophils. Panel C: Rat basophils
expressing hu FcεRI were pre-incubated with sera from 10 subjects
allergic birch and reacted with either rBet v 1 or AllerT (filled and
open symbols respectively). Results were grouped by IgE class levels
as determined by the ImmunoCAP assay (classes 4 to 6; n= 3 or 4
sera per class). Hexosaminidase release is expressed as the
percentage of release induced by anti-total IgE antiserum.
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shift, strongly indicating the absence of clinically relevant
IgE binding to AllerT.
Absence of detectable human basophil activation by COPs
In preparation for application to human subjects, AllerT
COPs and rBet v 1 were compared for their capacity to in-
duce human basophil degranulation. In a direct Basotest™
assay, blood was collected from patients allergic to birch
pollen and degranulation due to IgE crosslinking was
tested in response to COPs mixes, namely T1-T2-T3, T4-
T5 or T6-T7-T8 (Figure 4A). None of the COP mixes was
able to induce functional IgE crosslinking at any concen-
tration tested (up to 1 μM), whereas rBet v 1 induced 50%
degranulation already at about 0.1 nM. Thus AllerT dis-
plays an at least 104-fold lower capacity to activate baso-
phils from allergic patients.
In an alternative assay, basophils from a non-allergic
donor were pre-incubated with sera from birch pollen
allergic patients before being incubated with rBet v 1 in
an indirect Basotest™ assay (Figure 4B). Degranulation of
basophils loaded with IgE occurred at different Bet v 1
concentration, with EC50 ranging from about 0.01 to
over 1 nM. Again no basophil degranulation was detected
upon AllerT addition up to about 100 nM.
Finally, AllerT was tested against IgE from ten patients
allergic to birch pollen in an hexosaminidase release
assay using huFcεRI transfected RBL [29]. Degranulation
results were grouped by IgE serum levels (ImmunoCAP
classes, Figure 4C). Degranulation by rBet v 1 was clearly
IgE dose-dependent. A maximal response was reached
with a dose of 10-9 M rBet v 1, while no degranulation
was induced by AllerT up to 10-7 M in combination with
any of the 10 sera. Taken together these results con-
firmed that the COPs were unable to crosslink IgE.
Skin prick testing of birch pollen sensitive volunteers
(AN002 clinical trial)
Twenty subjects, 7 males and 13 females, mean age 30.1
years (range 23–45 years) (Table 2), were selected for
Table 2 AN002 clinical trial: volunteers’ characteristics
Parameters Characteristics
Number of volunteers 20
Mean age (range) 30.1 years (23–45)
Male /Female (nb/nb) 7 / 13
Allergic asthma (nb) 7
Allergic rhinitis (nb) 20
Mean peak expiratory flow rate (% predicted
value, L/min) (range)*
93.75 (61–117)
Mean anti-birch pollen IgE (kU/L) (range) 29.34 (0.7 – 100)
Mean anti-rBet v 1 IgE (kU/L) (range) 29.48 (0.35 - 100)
*Mean of three successive measurements.
Table 3 Skin prick test results according to EAACI
guidelines
A
Positive skin reactions (≥3 mm wheal and flare present)
Dilutions
1:1 1:10 1:100
Birch (100’000 SQ) 20 17 1
r Bet v 1 (1 μM) 20 16 2
T1 (10 μM) 0 0 0
T2 (10 μM) 0 0 0
T3 (10 μM) 0 0 0
AllerT (10 μM) 0 0 0
T4 (10 μM) 0 0 0
T5 (10 μM) 0 0 0
Mix T4-T5 (10 μM) 0 0 0
B
0 mm <Skin reaction < 3 mm
Dilutions
1:1 1:10 1:100
T1 (10 μM) 2 0 0
T2 (10 μM) 0 0 0
T3 (10 μM) 0 1 0
AllerT (10 μM) 0 0 0
T4 (10 μM) 0 0 1
T5 (10 μM) 1 0 0
Mix T4-T5 (10 2 μM) 6 0 1
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tive skin prick tests to birch pollen extract (Aquagen
SQ, ALK Abello). Skin prick tests with either birch
pollen extract (100’000 SQ) or rBet v 1 (1 μM) were
positive in all 20 volunteers (data not shown), namely
resulted in >3 mm wheal diameter with erythema [31].
Lowering allergen concentration by 10 fold resulted in
positive reactions in 85% and 80% of patients for birch
pollen extract and rBet v 1 respectively (Table 3),
whereas a further 10-fold dilution almost abolished skin
prick test reactivity. T1, T2, T3 COPs either alone or in
combination were unable to elicit skin prick test posi-
tive reactions even at a 10 μM concentration. These
data thus indicate that AllerT and individual COPs T1
to T3 were at least 100-fold less reactive in vivo than
rBet v 1.
The same result was obtained with the combination of
T4 and T5. However, when considering sub-threshold
reactions, namely wheal diameters of 2 to 3 mm, the T4-
T5 mix was reactive in 6 cases at the concentration of
10 μM.
Discussion
Although the efficacy of SIT has been well established,
there are still concerns on its safety and on the particularly
long duration of the treatment [4,5]. Despite improved
conventional protocols of SIT, severe anaphylactic reac-
tions may sometimes occur even in well-trained centers.
The duration of the therapy is another factor of discour-
agement for patients. The possibility to shorten the treat-
ment period, and to decrease the number of injections,
together with improved safety, would provide a consider-
ably more satisfying strategy for allergists to treat patients.
There have been so far several attempts to decrease
the allergenicity of immunotherapy products, including
so-called allergoid preparations [36-38], and more recently
T cell peptides, allergen fragments or mutated allergens. T
cell epitopes are short enough to stay unrecognized by IgE
in most cases, but are well recognized by T cell receptors.
They appear to induce tolerance in volunteers injectedintradermally with multi-T cell epitope preparations [16].
They did not induce immediate-type reactions but late re-
spiratory symptoms including dyspnea, which occurred a
few hours after the injections [39,40]. Long synthetic pep-
tides overlapping by 5 to 20 amino acids (COPs), as ap-
plied in the current study, were initially developed from
PLA2, the major bee venom allergen [17,18]. PLA2 hyper-
sensitive volunteers did not react to intradermal tests with
PLA2 derived long synthetic peptides. A phase I clinical
trial in bee venom hypersensitive patients was safe and in-
duced only transient late allergic reactions (sensation of
heat in two volunteers) and was immunogenic, namely in-
ducing a significant rise in PLA2 specific IgG4 [20]. In the
present study, the same approach was applied to Bet v 1,
the dominant allergen from birch pollen, a very common
respiratory allergy in Northern Europe. Three sets of pep-
tides were obtained, two consisting in three overlapping
peptides T1-T2-T3 and T6-T7-T8, another in two overlap-
ping peptides T4-T5. Their sequences were derived from
the most representative Bet v 1 isoform, rBet v 1.01A. The
interest of COPs relies in part in their capacity to cover all
potential T cell epitopes known to be spread all along the
Bet v 1 molecule [24], as previously observed also with
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fragments [15,41], overlapping of COPs prevents the loss
of T cell epitopes possibly located at the site of cleavage of
the fragments, thus avoiding the risk of any HLA
restriction [17]. Furthermore, the purity of the product,
compared to pollen extracts, insures the absence of con-
taminating allergens [42], endotoxins [43] and potentially
reduces the risk to induce IgE sensitization to uncon-
trolled components [44].
Peptide IgE binding capacity was first evaluated in
competition ELISA with human sera. The endpoint of
the assay was at least a ten-fold lower IgE binding activ-
ity of peptides as compared to recombinant Bet v 1, an
objective largely fulfilled here. Indeed, in comparison to
rBet v 1, we can estimate that AllerT showed at least a
107-fold lower ability to bind IgE. This value is below
values previously reported for hypoallergenic Bet v 1
variants, including folded variant [45], fragments [46] or
trimers [47].
We examined in parallel the capacity of AllerT to in-
duce anaphylactic reaction in a murine model. BALB/c
mice sensitized to rBet v 1 were not affected by the in-
traperitoneal injection of AllerT (at a five-fold higher
concentration than rBet v 1), whereas the i.p. injection
of rBet v 1 induced a sharp drop in rectal temperature, a
surrogate marker of anaphylaxis. These in vivo data
largely supported the results obtained with the rat baso-
phil leukemia cell line in vitro.
Although we cannot fully insure that anaphylactic
reaction was dependent on the induction of IgE, anti-
rBet v 1 specific murine IgE reached high titers after the
fourth subcutaneous injection as measured by ELISA
(Figure 3A). In parallel we also observed a strong in-
crease in rBet v 1 specific IgG1 and IgG2a. Massive
IgG1 activation has been shown to induce anaphylactic
shock in mice in the absence of IgE [48]. In contrast
IgG2a, a possible murine equivalent of IgG4 [49], may
antagonize allergen-IgE binding and protect against ana-
phylaxis. Despite the presence of both IgG1 and IgE
against rBet v 1 in sensitized mice, our combination of
COPs, AllerT, was unable to induce anaphylaxis in con-
trast to the recombinant allergen.
The low, if any, IgE binding activity of COPs as com-
pared to rBet v 1 was confirmed by a functional human
basophil activation assay as well as in an assay based on
huFcεRI transfected RBL. Using individual peptides as
well as their mixes, only background basophil or RBL
activation was noted in presence of sera from birch
pollen hypersensitive patients. Finally in in vivo assays,
twenty volunteers were tested by skin prick tests for re-
activity to Bet v 1, to birch pollen extract as well as to
the five COPs and their mixes (AllerT, T4-T5 mix). As
shown in Table 3, a decrease in skin sensitivity of about
10 to 100 folds was observed. This was true for T1 toT5 COPs individually. Interestingly, in 6 patients, the
mix of T4-T5 COPs was associated with a skin response
of 1 to 3 mm in diameter, in one patient for COP T5
only and in two patients for COP T1. Together with re-
sidual IgE binding activity in ELISA competition assays,
these results suggest a partial refolding of T4 and T5,
which potentially reconstitute the original IgE epitopes
in solution. This has already been observed for other
proteins [50,51]. This example shows the importance to
select for peptides with no detectable IgE binding either
in competition ELISA or degranulation tests before
going to human trial since possible re-association may
occur after in vivo injection as exemplified by the skin
prick tests reported in this study.Conclusions
Taken together, these experiments demonstrate that an al-
lergen specific immunotherapy strategy based on the in-
jection of selected COPs derived from Bet v 1 may be
applied to patients with hypersensitivity to birch pollen.
The presented data, performed both in murine and human
models, indicate that the binding of the selected COPs to
IgE, if any, is extremely limited. COPs were a) safe after
subcutaneous injection in sensitized mice since they did
not induce anaphylaxis, b) unable to activate human baso-
phils and c) did not induce prick test reactions. As com-
pared to birch pollen derived COPs T4 and T5, the mix of
COPs T1-T2-T3 (AllerT) appears as an optimal candidate
mix for a phase I clinical trial in birch pollen hypersensi-
tive patients with allergic rhinoconjunctivitis.
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